Rani Therapeutics Holdings, Inc.RANIEarnings & Financial Report
Rani Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing orally deliverable alternatives to injectable biologic therapies. Its core proprietary RaniPill technology is a robotic drug delivery capsule that administers large molecule drugs directly to the intestinal wall, eliminating the need for painful injections. The company serves patients with chronic conditions including diabetes, autoimmune disorders and osteoporosis, and collaborates with leading pharmaceutical partners to advance its product pipeline.
RANI Q3 FY2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-7.3M
Net Profit
$-5.4M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.12
Rani Therapeutics Holdings, Inc. Q3 FY2025 Financial Summary
Rani Therapeutics Holdings, Inc. reported revenue of $0 for Q3 FY2025, with a net profit of $-5.4M (up 20.2% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-5.4M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2025 |
Rani Therapeutics Holdings, Inc. Quarterly Revenue & Net Profit History
Rani Therapeutics Holdings, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $0 | — | $-5.4M | N/A |
| Q2 FY2025 | $0 | — | $-6.7M | N/A |
| Q1 FY2025 | $172.0K | — | $-7.3M | -4223.3% |
| Q3 FY2024 | $0 | — | $-6.8M | N/A |
| Q2 FY2024 | $0 | — | $-6.8M | N/A |
| Q1 FY2024 | $0 | — | $-7.5M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $172000 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | $53.5M | $43.7M | $43.5M | $24.1M | $16.9M | $10.1M |
| Liabilities | $39.0M | $38.2M | $37.8M | $29.5M | $26.1M | $22.1M |
| Equity | $7.4M | $2.8M | $3.1M | $-3.1M | $-5.6M | $-7.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-9.4M | $-9.0M | $-8.4M | $-8.1M | $-5.8M | $-5.1M |